1. Products
  2. Solutions
  3. Insights+
  4. News & content
  5. About
-
  1. Products
  2. Solutions
  3. Insights+
  4. News & content
  5. About
  1. Launch

ORIC Pharmaceuticals, Inc.

Have updates for this profile?  Please contribute data

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.

Year established

2014

Location

San Francisco CA US

Primary Industry

Biotechnology

About

Founded in 2014 and based in California, US, ORIC Pharmaceuticals, Inc. operates as a biopharmaceutical company. The company was founded by Richard Heyman, Charles Sawyers, and Scott Lowe. In January 2024, ORIC Pharmaceuticals, Inc. raised USD 125 million in PIPE funding from Viking Global Investors, New Enterprise Associates, and Commodore Capital. As of 2024, the company is led by its CEO, Jacob Chacko. ORIC Pharmaceuticals develops therapies to address cancer resistance. The firm’s pipeline project includes ORIC-114, an orally bioavailable inhibitor targeting EGFR and HER2 mutations, including those found in brain metastases; ORIC-944, a drug targeting a protein complex (PRC2) involved in several cancers, including prostate cancer; and ORIC-533, an inhibitor of CD73, an enzyme that suppresses the immune system's ability to attack cancer cells. The company plans to use the funds raised in January 2024 to support the advancement of its clinical-stage product candidates.
Current Investors
KKR, OrbiMed Advisors, Topspin Partners

Request a demo to show more

Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Molecular Science, Genetics & Gene Therapy, Oncology/Cancer Treatment
Website
www.oricpharma.com
Company Stage
Mature
Total Amount Raised
Subscriber access only

Deals

Deals Type
PIPE
Deal Status Target (s) Deal Date Investor(s) Seller(s) Deal size (Mn) Enterprise value (Mn) Post-money valuation (Mn) EBITDA multiple (x) Revenue multiple (x) Lead partner (s)
Completed ORIC Pharmaceuticals, Inc. 22 Jan 2024
Displaying 1-1 of 1

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.